My take...and I could be wrong, is that BK will not be paying for anything in the US. I understand the deal as GNBT pays the remaining expenses in the US. GNBT gets FDA approval. Then GNBT ships the vaccine, complete, accepted by the FDA, to BK and they assume all applications testing and approval responsibilities for the markets they licensed. I don’t know where you get Malaysian trials from. I see that all being in the US on GNBTs dime hence the importance of the upfront licensing fee. Maybe I’m just being pessimistic or maybe I’m rightfully being cautious. I don’t know. It seems like your hoping for the best and I’m preparing for the worst.